Semaglutide Hype or Hope: Evidence-based Review in Diabesity
Journal of The Association of Physicians of India · 2026-03 · 74 (3) · 103-107
DOI: 10.59556/japi.74.1439 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of The Association of Physicians of India, 2026-03. Verfasst von Sunil Gupta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Managing Director, Department of Diabetology, Nagpur, Maharashtra, India, Corresponding Author. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Managing Director, Department of Diabetology, Nagpur, Maharashtra, India, Corresponding Author.
- Senior Physician, Diabetologist and Obesity Specialist, Dr Makkar's Diabetes and Obesity Centre, Delhi, India.
- Chairman and Managing Director, Jothydev's Diabetes Research Center, Trivandrum, Kerala, India.
- Senior Diabetologist, Diabetes Care and Research Centre, Patna, Bihar, India.
Zitieren
APA
Gupta, S., Makkar, B. M., Kesavadev, J., & Kumar, A. (2026). Semaglutide Hype or Hope: Evidence-based Review in Diabesity. Journal of The Association of Physicians of India, 74(3), 103-107. https://doi.org/10.59556/japi.74.1439
Vancouver
Gupta S, Makkar BM, Kesavadev J, Kumar A. Semaglutide Hype or Hope: Evidence-based Review in Diabesity. Journal of The Association of Physicians of India. 2026;74(3):103-107. doi:10.59556/japi.74.1439
BibTeX
@article{Gupta2026,
author = {Gupta, Sunil and Makkar, Brij Mohan and Kesavadev, Jothydev and Kumar, Ajay},
title = {Semaglutide Hype or Hope: Evidence-based Review in Diabesity},
journal = {Journal of The Association of Physicians of India},
year = {2026},
volume = {74},
number = {3},
pages = {103--107},
doi = {10.59556/japi.74.1439}
}
EUVIMED